AstraZeneca and Ionis Think They Have A Best-In-Class PCSK9 Challenger To Novartis’s Leqvio
Study Shows 73% Reduction in LDL Cholesterol
AstraZeneca and Ionis believe they have a potential best-in-class PCSK9 inhibitor, but the product will have to impress in forthcoming pivotal trials to catch up with Novartis’s Leqvio.
You may also be interested in...
While the Phase IIb SOLANO trial of ION449 met its primary endpoint, AstraZeneca had set a high bar of 70% LDL cholesterol reduction for competitiveness that the study did not hit.
The company dosed the first patient in its study of base editor VERVE-101, a possible single-dose treatment for HeFH that joins a growing list of PCSK9-targeted therapy candidates.
The US pharma giant is planning ahead for Keytruda’s swansong, and hopes that wave of new cardiovascular drugs can help maintain its growth into the next decade.